Treatment of pain remains a major unmet medical need. Opiate drugs continue to be the most important therapies for the treatment of moderate to severe pain but suffer from severe side effects that diminish quality of life. It is known that neurons in the pain transmission and modulatory pathways undergo plasticity that results in amplification of pain signaling in settings of tissue injury (i.e. the conditions in which pain relieving drugs are used). Unexpectedly, such pronociceptive adaptations also occur as a consequence of repeated exposure to opiates. Increased signaling through the substance P-NK1 pathway strongly contributes to peripheral and central sensitization to enhance pain. This multidisciplinary proposal involving five different laboratories, is aimed at testing the hypothesis that pain relieving drugs can be designed with a priori consideration of mechanisms of amplification that diminish desired analgesia, i.e., drug design for disease. We hypothesize that drugs that have opioid agonist (mostly mu) and NK-1 antagonist activity within a single molecule would provide effective pain relief, particularly in conditions of chronic pain with diminished side effects allowing for greater tolerability and increased quality of life. Thus, we propose to exploit recent developments in our de novo design and pain-related pharmacology, physiology and molecular biology to develop new classes of peptidomimetic ligands with a profile of mu/delta opioid receptor agonist activities and neurokinin 1 antagonist activities.
Our Specific Aims are:
Aim 1 : To design, synthesize and characterize novel metabolically stable and systemically active bifunctional ? preferring ?/4 opioid agonist ligands with NK-1 antagonist activities based on TY027, a current lead compound (delta opioid agonist preferring/NK1 antagonist). Biophysical studies (NMR, CD, PWR, etc.) in conjunction with computational chemistry will be used to evaluate 3-D conformations critical to bioactivity.
Aim 2 will characterize the pharmacology of these compounds in vitro and in vivo for (a) analgesic/antihyperalgesic efficacy;(b) propensity for developing antinociceptive tolerance and opioid-induced hyperalgesia;(c) sedation;(d) gastrointestinal side effects;and (f) addictive liability.
Aim 3 will evaluate the (a) metabolic stability of our novel compounds, (b) perform pharmacokinetic analysis, (c) evaluate BBB penetration and whether the compounds are substrates for P- glycoproteins, and (d) perform a broad screen for possible off-target activities. Our goal will be to discover a highly efficacious ligand, and backup ligand, that can be brought forward as a preclinical drug candidate during this grant period.

Public Health Relevance

This grant involving 5 principal investigators will develop a novel class of bioavailable ligands that can treat long term and neuropathic pain without the development of tolerance or drug seeking behavior These novel compounds will lack other undesirable side effects and toxicities of current drugs for treating pain. These compounds have mu/delta opioid agonist activities and neurokinin-1 antagonist activities providing a new approach to acute and chronic pain treatment. A clinical candidate will be identified during this grant period.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA013449-13S1
Application #
8604331
Study Section
Special Emphasis Panel (ZRG1 (91))
Program Officer
Hillery, Paul
Project Start
2000-09-01
Project End
2016-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
13
Fiscal Year
2013
Total Cost
$24,593
Indirect Cost
$8,360
Name
University of Arizona
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Lee, Yeon Sun; Muthu, Dhanasekaran; Hall, Sara M et al. (2014) Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord. J Am Chem Soc 136:6608-16
Giri, Aswini Kumar; Hruby, Victor J (2014) Investigational peptide and peptidomimetic * and ýý opioid receptor agonists in the relief of pain. Expert Opin Investig Drugs 23:227-41
Lee, Yeon Sun; Rankin, David; Hall, Sara M et al. (2014) Structure-activity relationships of non-opioid [des-Arg(7)]-dynorphin A analogues for bradykinin receptors. Bioorg Med Chem Lett 24:4976-9
Vardanyan, Ruben S; Hruby, Victor J (2014) Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med Chem 6:385-412
Fernandes, Steve M; Lee, Yeon Sun; Gillies, Robert J et al. (2014) Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor. Bioorg Med Chem 22:6360-5
Nair, Padma; Yamamoto, Takashi; Largent-Milnes, Tally M et al. (2013) Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg Med Chem Lett 23:4975-8
Largent-Milnes, T M; Brookshire, S W; Skinner Jr, D P et al. (2013) Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther 347:7-19
Brabez, Nabila; Saunders, Kara; Nguyen, Kevin L et al. (2013) Multivalent Interactions: Synthesis and Evaluation of Melanotropin Multimers - Tools for Melanoma Targeting. ACS Med Chem Lett 4:98-102
Hruby, Victor J; Cai, Minying (2013) Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles. Annu Rev Pharmacol Toxicol 53:557-80
Podolsky, Alexander T; Sandweiss, Alexander; Hu, Jackie et al. (2013) Novel fentanyl-based dual ?/?-opioid agonists for the treatment of acute and chronic pain. Life Sci 93:1010-6

Showing the most recent 10 out of 75 publications